75% of women with unexplained infertility will test postive for BCL6

What is ReceptivaDx™?

ReceptivaDxTM is a first of its kind test for the detection of inflammation of the uterine lining most commonly associated with endometriosis, a leading cause of infertility and implantation failure.

Women testing positive for ReceptivaDx are 5 times less likely to succeed in IVF than women testing negative.

ReceptivaDxTM (BCL6 Test) Predicts Chances for a Successful Transfer and Successful Pregnancy

How can the ReceptivaDx™ test help me?

High levels of BCL6 indicates inflammation usually associated with endometriosis, limiting the ability of the embryo to stick to the endometrial lining.

If endometriosis is suspected it can be treated by your physician. Current treatments include hormone therapy or laparoscopy. Patients can then resume pregnancy attempts shortly after with renewed confidence.

A negative BCL6 result provides reassurance to patients that endometriosis is not of concern and that future attempts at pregnancy are likely to be successful.

While other tests evaluate the quality of embryos or determine optimal embryo transfer windows, only ReceptivaDx™ can accurately detect inflammatory conditions on the uterine lining likely to cause implantation issues.

Why is ReceptivaDx™ testing Important?

For many women, the detection of endometriosis comes as a complete surprise. Although endometriosis has long been associated with pelvic pain, the majority of women testing positive for BCL6 had no other symptoms except for their recent fertility issues.

 

Before ReceptivaDx™, the only way to detect endometriosis was via laparoscopy, an expensive and invasive procedure not routinely offered unless major physical symptoms were present.

ReceptivaDx™ (BCL6 Test) Predicts Chances for a Successful Transfer and Successful Pregnancy

Women testing positive for ReceptivaDx:

• Less than 18% Pregnancy rate in next transfer attempt
• Less than 11% Success rate resulting in live birth

Women testing negative for ReceptivaDx:

• More than 70% Pregnancy rate in next transfer attempt
• More than 59% Success rate resulting in live birth

In a recent study published in the December 2017 issue of Fertility & Sterility, the official journal of the American Society of Reproductive Medicine (ASRM*), BCL6 was able to identify women with a poor prognosis for IVF success and a successful pregnancy if left undetected and untreated.

 

*Endometrial BCL6 testing for the prediction of in vitro fertilization outcomes: a cohort study. Almquist LD, Likes CE, Stone B, Brown KR, Savaris R, Forstein DA, Miller PB, Lessey BA Fertil Steril. 2017 Dec;108(6):1063-1069

The ReceptivaDxTM Test was developed by CiceroDx in conjunction with Pathology Consultants, Inc. of Greenville, SC. Pathology Consultants, Inc. is a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). As with other laboratory-developed tests, this testing service has not been cleared or approved by the US FDA or any other federal regulatory agencies. Data have not been submitted to or evaluated by Federal regulatory agencies and the test is not for sale as an In Vitro Diagnostic (IVD) in the US or the EU.


Copyright © 2019 ReceptivaDx™ | All Rights Reserved